Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144053
Status:
COMPLETED
Last Update Posted:
2006-01-06
First Post:
2005-08-31
Brief Title:
A Phase Ⅲ Randomized Study of MitomycinVindesineCisplatin Versus IrinotecanCarboplatin Versus PaclitaxelCarboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
Sponsor:
West Japan Thoracic Oncology Group
Organization:
West Japan Thoracic Oncology Group
Study Overview
Official Title:
A Phase Ⅲ Randomized Study of MitomycinVindesineCisplatin Versus IrinotecanCarboplatin Versus PaclitaxelCarboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin Vindesine Mitomycin for unresectable stage III NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None